Cancer clinical trials in the region Grand Est

291 currently recruiting clinical trials
Region Grand Est

Phase 2 Multiple myeloma #NCT05572229 #2022-001594-31
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
18 recruiting sites
Hôpital universitaire de Lille
Phase 2 Lung cancer #NCT06855771 #2024-519814-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Bristol-Myers Squibb
Phase 2 Thyroid and adrenal gland cancer #NCT03732495
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma Poorly differentiated carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Radioactive iodine
Required radioactive iodine status
Resistant to radioactive iodine
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
14 recruiting sites
Centre Léon Bérard
Phase 2 Lung cancer #NCT04613596 #2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT06172478 #2023-507641-29-00
Required histologic types
Invasive bladder cancer Upper excretory tract cancer Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Colon cancer Rectal cancer Anal cancer #NCT04954820
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
1
Required SSTR metabolic imaging statuses
SSTR Positive
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
26 recruiting sites
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Pancreas cancer Stomach and esophageal cancer #NCT04325425 #2024-515300-39-00
Required histologic types
Stomach
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
14 recruiting sites
CHU Dijon
Phase 2 Breast cancer #NCT05973864 #2023-505291-30-01
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery Immunotherapy Chemotherapy
20 recruiting sites
UNICANCER
Phase 2 Lymphoma #NCT04844866
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Primary mediastinal lymphoma Follicular lymphoma Indolent transformed lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
Required previous treatments
Chemotherapy Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive Car-T
5 recruiting sites
Miltenyi Biomedicine GmbH
Phase 2 Stomach and esophageal cancer Sarcoma and GIST #NCT05152472 #2022-503068-34-00
Required histologic types
GIST
Required histologic sub types
Gastrointestinal stromal tumor
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy
12 recruiting sites
Centre Léon Bérard